Global strategy for access to health technologies in developing countries under review
The global strategy on public health, innovation and intellectual property (GSPOA) and the related plan of action were adopted in 2009 and are intended to enable low- and middle-income countries to have greater and more sustainable access to the medical products they need – medicines, vaccines and other health technologies. Guided by the central concept of needs-driven essential health research and development, the GSPOA represents the first comprehensive framework and promise of long-term funding to support countries’ strategies for pharmaceutical innovation. The GSPOA went through an evaluation in 2016. The current review, based on the evaluation, aims to clarify the GSPOA’s feasibility as a model and identify areas for potential improvement.
WHO finds India’s vaccine regulatory authority compliant with international standards
A team of international experts convened by WHO recently found India’s National Regulatory Authority (NRA) to meet WHO standards for vaccine regulation. This effectively means that India is well equipped to produce and monitor safe, effective and quality vaccines, and will facilitate WHO prequalification of Indian manufacturers, which will allow them to supply vaccines through the international procurement system.
Snakebite gaining momentum – access to quality antivenoms a top priority
One of today’s most neglected health problems, snakebite-induced death and disability, impacts on the lives of thousands, mostly the rural poor, and contributes to multiple issues that challenge subsistence agriculture and the overall quality of life in many settings. WHO has for several years advocated for greater attention to the issue, including the need for a broader public health approach to tackling snakebite envenoming that focuses on prevention, education and management. In addition, WHO has developed a large body of guidelines, in particular on the quality manufacture of antivenoms.
WHO proposal to establish a WHO Model List of Essential In Vitro Diagnostics (EDL)
Building on the WHO Model List of Essential Medicines (EML), WHO is proposing to establish a WHO Model List of Essential In Vitro Diagnostics (EDL). A proposal has been submitted to the 21st WHO Expert Committee on the Selection and Use of Essential Medicine for comments and recommendations about the relevance, scope and the best course of action for developing the EDL.
This Expert Committee will meet on 27-31 March 2017 in Geneva.
New: School of INN Video
In many countries, different brand names are used for the same medicine. The International Nonproprietary Name (INN) programme was set up to provide a common and an official generic name for each and every medicine. In a highly globalized world, the use of INNs, rather than medicines brand names, are critical for health care professionals as well as patients.
Fair pricing of medicines and fair pricing forum
Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics
Request for Proposals: Development and implementation of the Essential Medicines Portal and Essential Medicines List online management solution” (eEML)